Newsletters

Newsletters

Spring 2017 Newsletter

We’ve got spring feVRE! Many bacteria live in our gut and on our skin, usually without causing problems. However, serious infections can occur when these bacteria become resistant to antibiotics. Vancomycin-resistant enterococci, or VRE, are one such threat. Although healthy people are unlikely to become infected with VRE, those who are hospitalized or have weakened immune systems are especially at risk. TransPharm has a well-established murine model of VRE colonization in the gastrointestinal tract, one of the most common sites for infection. Antibiotic pre-treatment provides consistent results, with fecal shedding peaking on Days 3-5 and observed through Day 15. Our screening studies are flexible enough to accommodate studies with prophylactic and/or daily dosing. We also have personnel and areas of our facility dedicated specifically to VRE work. Contact us today for a quote!

read more

Winter 2017 Newsletter

January 2017 marked our 9 year anniversary and the close of another great year here at TransPharm. With 17 new clients in 2016, the TransPharm family now spans over 6 continents. As a result of our continued growth, we were able to reach a major milestone in November: a total of $10M in revenue since I founded the company in 2008. Increased demand also allowed us to welcome some new faces to our team – Brianne Fiero (Associate Scientist) in April, and Brittany Dixon (Scientific Writer) and Emily Gilles (Laboratory Technician) in October. 2016 was also a year of physical growth. A 2,100 sq. ft. addition to our facility, including an expanded animal vivarium and a procedure room, was completed in May. This new space contains both a negative pressure room and a positive pressure room, with corresponding bioBUBBLE® enclosures in each, meaning separate, dedicated areas for C. difficile and germ-free work, respectively. The renovations have already proven advantageous to our clients who currently work in the C. difficile therapy development field. Please contact us for more information.

read more

Fall 2014 Newsletter

Another year has gone by and 2015 is right around the corner. This January marks our seven-year anniversary. It is hard to believe that eight years has passed since Pfizer closed its doors in Ann Arbor, Michigan. January 22nd, 2007 was the announcement day that made all of us wonder what would happen after Pfizer. I was one of the lucky ones that had a plan shortly after the announcement and that plan was founding TransPharm Preclinical Solutions. We incorporated on April 13th, 2007, started renovation to the lab in September of that year, and opened our doors on January 2nd, 2008. Today we are considered a global leader for Infectious Disease research and have generated more than $6 million in revenue with over 60 clients around the world. TransPharm has never been stronger and we are eager to see what the future holds for us. During the holidays, we are very thankful to do what we love and even more thankful to you for allowing us to do this important work.

read more

Summer 2014 Newsletter

I would like to wish a happy summer to all of you. As we move into warmer weather, vacations and outdoor activities fill our days and time to get things done seems to shorten. Towards that end, I will be brief with this newsletter and announce that TransPharm has finally been awarded PHS registry with the Office of Laboratory Animal Welfare. This means that companies receiving grants from NIH are now allowed to spend those funds directly with TransPharm Preclinical Solutions. This is a huge milestone for us and I know it will open the doors to many smaller companies receiving grant funds. Please see the notice below and use our Assurance #A4707-01 for all future grant applications to the National Institute of Health.

read more

Spring 2014 Newsletter

Over the past several quarters, the TransPharm team has been busy performing numerous C. difficile studies and looking for ways to best serve our clients’ needs. As a result, we’ve added two new offerings to complement our robust model of C. difficile infection. These new features are Toxin A/B detection and recurrence studies. We feel these two new, clinically-relevant features will be advantageous to our clients who currently work in the C. difficile therapy development field. Please contact us for more information.

read more

Contact Us

10 + 11 =

science exchange logo

scientist.com logo

Jackson Certified
Brooklyn-Irish Hills Chamber of Commerce logo